Human pituitary adenomas are the most common intracranial neoplasms. Approximately 5%
of them are familial adenomas. Patients with familial tumors carry germline mutations in …

The delay in controlling the disease in patients who do not respond to first-line treatment
with first generation somatostatin receptor ligands (first-generation SRLs) can be quantified …

The molecular mechanisms leading to aryl hydrocarbon receptor interacting protein (AIP)
mutation-induced aggressive, young-onset growth hormone-secreting pituitary tumors are …

Pharmacologic treatment of acromegaly is currently based upon assay-error strategy, the
first-generation somatostatin receptor ligands (SRL) being the first-line treatment. However …

Cases with pituitary adenoma comprise 10–25% of intracranial neoplasm, being the third
most common intracranial tumor, most of the adenomas are considered to be benign. About …

Pituitary adenomas are the second most common primary brain tumor with invasive
properties. We have previously identified that ADAM12 (a disintegrin and metalloprotease …

Growth hormone (GH) pituitary tumors are associated with significant morbidity and
mortality. Current treatments, including surgery and medical therapy with somatostatin …

The pituitary tumour microenvironment encompasses a spectrum of non-tumoural cells, such
as immune, stromal or endothelial cells, as well as enzymes and signalling peptides like …

The microenvironment of pituitary adenomas (PAs) includes a range of non-tumoral cells,
such as immune and stromal cells, as well as cell signaling molecules such as cytokines …

Context Previous studies have implicated growth hormone (GH) in the progression of
several cancers, including breast, colorectal, and pancreatic. A mechanism by which GH …